[en] Atrial fibrillation (AF) and heart failure (HF) are common cardiovascular conditions that frequently coexist. Among patients with HF, more than one-half also have AF. Both are associated with significant morbidity and mortality. Moreover, the prevalence of each is increasing globally, and this trend is expected to continue owing to an aging population and increased life expectancy. Diagnosis of AF in a patient with HF is associated with greater symptom burden, more frequent hospitalizations, and a worse prognosis. Guideline-directed medical therapy (GDMT) for HF can affect the incidence of AF. Once present, AF can influence the efficacy of some components of GDMT for HF. In this review, we discuss the effect of GDMT for HF across the spectrum of ejection fraction on prevention of AF as well as the benefit of GDMT in patients with vs without AF.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Newman, Joshua D; Endeavor Health, Glenview, Illinois, USA.
O'Meara, Eileen; Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada.
Böhm, Michael; University of the Saarland, Homberg/Saar, Germany.
Savarese, Gianluigi; Division of Cardiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden, Heart and Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.
Kelly, Patricia R; Missoula Cardiology, Missoula, Montana, USA.
Vardeny, Orly; University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Allen, Larry A; Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Gottlieb, Stephen S; Division of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA, Baltimore Veterans Administration Medical Center, Baltimore, Maryland, USA.
Samad, Zainab; Aga Khan University, Karachi, Pakistan.
Morris, Alanna A; Emory University School of Medicine, Atlanta, Georgia, USA.
Desai, Nihar R; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Rosano, Giuseppe M C; Center for Clinical and Basic Research, IRCCS San Raffaele Pisana, Rome, Italy.
Teerlink, John R; University of California, San Francisco, California, USA.
Giraldo, Clara Saldarriaga; University of Antioquia, Medellin, Colombia.
Lindenfeld, JoAnn; Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: joann.lindenfeld@vumc.org.
Tsao, C.W., Aday, A.W., Almarzooq, Z.I., et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation 145:8 (2022), e153–e639.
Krijthe, B.P., Kunst, A., Benjamin, E.J., et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 34:35 (2013), 2746–2751.
Colilla, S., Crow, A., Petkun, W., Singer, D.E., Simon, T., Liu, X., Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 112:8 (2013), 1142–1147.
McDonagh, T.A., Metra, M., Adamo, M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:36 (2021), 3599–3726.
Bassi, N.S., Ziaeian, B., Yancy, C.W., Fonarow, G.C., Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol 5:8 (2020), 948–951.
Savarese, G., Kishi, T., Vardeny, O., et al. Heart failure drug treatment—inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). J Am Coll Cardiol HF 11:1 (2023), 1–14.
Santhanakrishnan, R., Wang, N., Larson, M.G., et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133:5 (2016), 484–492.
Ponikowski, P., Alemayehu, W., Oto, A., et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. Eur J Heart Fail 23:8 (2021), 1300–1312.
Butt, J.H., Docherty, K.F., Jhund, P.S., et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail 24:3 (2022), 513–525.
Hindricks, G., Potpara, T., Dagres, N., et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 42:5 (2021), 373–498.
Carlisle, M.A., Fudim, M., DeVore, A.D., Piccini, J.P., Heart failure and atrial fibrillation, like fire and fury. J Am Coll Cardiol HF 7:6 (2019), 447–456.
Wang, N., Yu, Y., Sun, Y., et al. Acquired risk factors and incident atrial fibrillation according to age and genetic predisposition. Eur Heart J 44:47 (2023), 4982–4993.
Tromp, J., Paniagua, S.M.A., Lau, E.S., et al. Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ, 372, 2021, n461.
Sartipy, U., Dahlström, U., Fu, M., Lund, L.H., Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. J Am Coll Cardiol HF 5:8 (2017), 565–574.
Iwasaki, Y.K., Nishida, K., Kato, T., Nattel, S., Atrial fibrillation pathophysiology: Implications for management. Circulation 124:20 (2011), 2264–2274.
Denham, N.C., Pearman, C.M., Caldwell, J.L., et al. Calcium in the pathophysiology of atrial fibrillation and heart failure. Front Physiol, 9, 2018, 1380.
Deferm, S., Bertrand, P.B., Verbrugge, F.H., et al. Atrial functional mitral regurgitation: JACC review topic of the week. J Am Coll Cardiol 73:19 (2019), 2465–2476.
Utsunomiya, H., Itabashi, Y., Mihara, H., et al. Functional tricuspid regurgitation caused by chronic atrial fibrillation: a real-time 3-dimensional transesophageal echocardiography study. Circ Cardiovasc Imaging, 10(1), 2017, e004897.
Kaur, K., Zarzoso, M., Ponce-Balbuena, D., et al. TGF-β1, released by myofibroblasts, differentially regulates transcription and function of sodium and potassium channels in adult rat ventricular myocytes. PLoS One, 8(2), 2013, e55391.
Shahid, F., Lip, G.Y.H., Shantsila, E., Renin-angiotensin blockade in atrial fibrillation: where are we now?. J Hum Hypertens 31:7 (2017), 425–426.
Huizar, J.F., Ellenbogen, K.A., Tan, A.Y., Kaszala, K., Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73:18 (2019), 2328–2344.
Anter, E., Jessup, M., Callans, D.J., Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 119:18 (2009), 2516–2525.
Gertz, Z.M., Herrmann, H.C., Lim, D.S., et al. Implications of atrial fibrillation on the mechanisms of mitral regurgitation and response to MitraClip in the COAPT trial. Circ Cardiovasc Interv, 14(4), 2021, e010300.
Stone, G.W., Lindenfeld, J., Abraham, W.T., et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379:24 (2018), 2307–2318.
Kotecha, D., Lam, C.S.P., van Veldhuisen, D.J., van Gelder, I.C., Voors, A.A., Rienstra, M., Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol 68:20 (2016), 2217–2228.
Zafrir, B., Lund, L.H., Laroche, C., et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J 39:48 (2018), 4277–4284.
Eapen, Z.J., Greiner, M.A., Fonarow, G.C., et al. Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. Am Heart J 167:3 (2014), 369–375.e2.
Olsson, L.G., Swedberg, K., Ducharme, A., et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. results from the Candesartan in Heart Failure—Assessment of Reduction in Mortality and Morbidity (CHARM) Program. J Am Coll Cardiol 47:10 (2006), 1997–2004.
Inciardi, R.M., Giugliano, R.P., Park, J.G., et al. Risks of heart failure, stroke, and bleeding in atrial fibrillation according to heart failure phenotypes. J Am Coll Cardiol EP 9:4 (2023), 569–580.
Linssen, G.C.M., Rienstra, M., Jaarsma, T., et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 13:10 (2011), 1111–1120.
Steinberg, B.A., Li, Z., O'Brien, E.C., et al. Atrial fibrillation burden and heart failure: data from 39,710 individuals with cardiac implanted electronic devices. Heart Rhythm 18:5 (2021), 709–716.
Wong, J.A., Conen, D., van Gelder, I.C., et al. Progression of device-detected subclinical atrial fibrillation and the risk of heart failure. J Am Coll Cardiol 71:23 (2018), 2603–2611.
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:23 (1987), 1429–1435.
SOLVD Investigators Yusuf, S., Pitt, B., Davis, C.E., Hood, W.B., Cohn, J.N., Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:10 (1992), 685–691.
SOLVD Investigators Yusuf, S., Pitt, B., Davis, C.E., Hood, W.B., Cohn, J.N., Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:5 (1991), 293–302.
Cohn, J.N., Tognoni, G., Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:23 (2001), 1667–1675.
Pfeffer, M.A., Swedberg, K., Granger, C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 362:9386 (2003), 759–766.
Heidenreich, P.A., Bozkurt, B., Aguilar, D., et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79:17 (2022), e263–e421.
Ehrlich, J.R., Hohnloser, S.H., Mattel, S., Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27:5 (2006), 512–518.
He, X., Gao, X., Peng, L., et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ Res 108:2 (2011), 164–175.
Ravelli, F., Allessie, M., Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 96:5 (1997), 1686–1695.
Dewland, T.A., Soliman, E.Z., Yamal, J.M., et al. Pharmacologic prevention of incident atrial fibrillation: long-term results from the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Circ Arrhythm Electrophysiol, 10(12), 2017, e005463.
Vermes, E., Tardif, J.C., Bourassa, M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107:23 (2003), 2926–2931.
Pedersen, O.D., Bagger, H., Kober, L., Torp-Pedersen, C., Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:4 (1999), 376–380.
Alsheikh-Ali, A.A., Wang, P.J., Rand, W., et al. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J 147:6 (2004), 1061–1065.
Maggioni, A.P., Latini, R., Carson, P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149:3 (2005), 548–557.
Ducharme, A., Swedberg, K., Pfeffer, M.A., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Am Heart J 152:1 (2006), 86–92.
McMurray, J.J.V., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:11 (2014), 993–1004.
Solomon, S.D., Vaduganathan, M., Claggett, B.L., et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141:5 (2020), 352–361.
Dong, Y., Zhai, Z., Wang, J., et al. Angiotensin receptor–neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation. Sci Rep, 13(1), 2023, 3140.
Cheng, W.H., Lugtu, I.C., Chang, S.L., Liu, S.H., Chen, S.A., Lo, L.W., Effects of angiotensin receptor-neprilysin inhibitor in arrhythmogenicity following left atrial appendage closure in an animal model. Cardiovasc Drugs Ther 35:4 (2021), 759–768.
Li, L.Y.F., Lou, Q., Liu, G.Z., et al. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. Eur J Pharmacol, 881, 2020, 173120.
Liu, X., Liu, H., Wang, L., Zhang, L., Xu, Q., Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: a systematic review and metaanalysis of randomized controlled trials. PLoS One, 17(1), 2022, e0263131.
Cikes, M., Planinc, I., Claggett, B., et al. Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial. J Am Coll Cardiol HF 10:5 (2022), 336–346.
Yang, L., Zhang, M., Hao, Z., Wang, N., Zhang, M., Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients. ESC Heart Fail 9:4 (2022), 2428–2434.
Suo, Y., Yuan, M., Li, H., et al. Sacubitril/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload–induced mice. Front Pharmacol, 10, 2019, 1285.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9146 (1999), 9–13.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:9169 (1999), 2001–2007.
Packer, M., Fowler, M.B., Roecker, E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 106:17 (2002), 2194–2199.
Cleland, J.G.F., Bunting, K.V., Flather, M.D., et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39:1 (2018), 26–35.
Palau, P., Seller, J., Domínguez, E., et al. Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol 78:21 (2021), 2042–2056.
Silverman, D.N., Plante, T.B., Infeld, M., et al. Association of β-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial. JAMA Netw Open, 2(12), 2019.
January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:21 (2014), e1–76.
Flather, M.D., Gollop, N.D., Understanding mechanisms of action of beta-blockers in heart failure with reduced and preserved ejection fraction. J Am Coll Cardiol HF 4:2 (2016), 150–151.
Michaud, G.F., Stevenson, W.G., Atrial fibrillation. N Engl J Med 384:4 (2021), 353–361.
Kühlkamp, V., Bosch, R., Mewis, C., Seipel, L., Use of beta-blockers in atrial fibrillation. Am J Cardiovasc Drugs 2:1 (2002), 37–42.
Nasr, I.A., Bouzamondo, A., Hulot, J.S., Dubourg, O., le Heuzey, J.Y., Lechat, P., Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 28:4 (2007), 457–462.
McMurray, J., Køber, L., Robertson, M., et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45:4 (2005), 525–530.
Rienstra, M., Damman, K., Mulder, B.A., van Gelder, I.C., McMurray, J.J.V., van Veldhuisen, D.J., Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. J Am Coll Cardiol HF 1:1 (2013), 21–28.
Kotecha, D., Holmes, J., Krum, H., et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384:9961 (2014), 2235–2243.
Nielsen, P.B., Larsen, T.B., Gorst-Rasmussen, A., Skjøth, F., Lip, G.Y.H., β-Blockers in atrial fibrillation patients with or without heart failure: association with mortality in a nationwide cohort study. Circ Heart Fail, 9(2), 2016, e002597.
Cadrin-Tourigny, J., Shohoudi, A., Roy, D., et al. Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: an AF-CHF substudy. J Am Coll Cardiol HF 5:2 (2017), 99–106.
Pal, N., Sivaswamy, N., Mahmod, M., et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation 132:18 (2015), 1719–1725.
Kotecha, D., Altman, D.G., Rosano, G., Flather, M.D., Observational versus randomized: sliding toward nonevidence-based medicine. J Am Coll Cardiol HF 5:5 (2017), 395–396.
Parviz, Y., Iqbal, J., Pitt, B., Adlam, D., Al-Mohammad, A., Zannad, F., Emerging cardiovascular indications of mineralocorticoid receptor antagonists. Trends Endocrinol Metab 26:4 (2015), 201–211.
Staessen, J., Lijnen, P., Fagard, R., Verschueren, L.J., Amery, A., Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91:3 (1981), 457–465.
Zannad, F., McMurray, J.J.V., Krum, H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:1 (2011), 11–21.
Pitt, B., Remme, W., Zannad, F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:14 (2003), 1309–1321.
Pitt, B., Zannad, F., Remme, W.J., et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:10 (1999), 709–717.
Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:15 (2014), 1383–1392.
Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131:1 (2015), 34–42.
Solomon, S.D., Claggett, B., Lewis, E.F., et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37:5 (2016), 455–462.
Milliez, P., Girerd, X., Plouin, P.F., Blacher, J., Safar, M.E., Mourad, J.J., Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:8 (2005), 1243–1248.
Reil, J.C., Hohl, M., Selejan, S., et al. Aldosterone promotes atrial fibrillation. Eur Heart J 33:16 (2012), 2098–2108.
Swedberg, K., Zannad, F., McMurray, J.J.V., et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) study. J Am Coll Cardiol 59:18 (2012), 1598–1603.
Neefs, J., van den Berg, N.W.E., Krul, S.P.J., Boekholdt, S.M., de Groot, J.R., Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT Trial. Am J Cardiovasc Drugs 20:1 (2020), 73–80.
Cikes, M., Claggett, B., Shah, A.M., et al. Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial. J Am Coll Cardiol HF 6:8 (2018), 689–697.
Shantsila, E., Shahid, F., Sun, Y., et al. Spironolactone in atrial fibrillation with preserved cardiac fraction: the IMPRESS-AF trial. J Am Heart Assoc, 9(18), 2020, e016239.
Filippatos, G., Bakris, G.L., Pitt, B., et al. Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol 78:2 (2021), 142–152.
Filippatos, G., Anker, S.D., Agarwal, R., et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation 145:6 (2022), 437–447.
Zannad, F., Ferreira, J.P., Pocock, S.J., et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396 (2020), 819–829.
McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:21 (2019), 1995–2008.
Packer, M., Anker, S.D., Butler, J., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:15 (2020), 1413–1424.
Solomon, S.D., McMurray, J.J.V., Claggett, B., et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:12 (2022), 1089–1098.
Anker, S.D., Butler, J., Filippatos, G., et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:16 (2021), 1451–1461.
Kubota, Y., Shimizu, W., Clinical benefits of sodium–glucose cotransporter 2 inhibitors and the mechanisms underlying their cardiovascular effects. JACC Asia 2:3 Part 2 (2022), 287–293.
Zelniker, T.A., Bonaca, M.P., Furtado, R.H.M., et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation 141:15 (2020), 1227–1234.
Sato, T., Aizawa, Y., Yuasa, S., et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol, 17(1), 2018, 6.
Filippatos, G., Farmakis, D., Butler, J., et al., EMPEROR-Preserved Trial Committees and Investigators. Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. Eur J Heart Fail 25:7 (2023), 970–977.
Butt, J.H., Kondo, T., Jhund, P.S., et al. Atrial fibrillation and dapagliflozin efficacy in patients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 80:18 (2022), 1705–1717.
Gheorghiade, M., Adams, K.F., Colucci, W.S., Digoxin in the management of cardiovascular disorders. Circulation 109:24 (2004), 2959–2964.
Gheorghiade, M., Fonarow, G.C., van Veldhuisen, D.J., et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 34:20 (2013), 1489–1497.
Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:8 (1997), 525–533.
Ahmed, A., Rich, M.W., Love, T.E., et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27:2 (2006), 178–186.
Whitbeck, M.G., Charnigo, R.J., Khairy, P., et al. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur Heart J 34:20 (2013), 1481–1488.
Kapelios, C.J., Lund, L.H., Benson, L., et al. Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry. Eur Heart J Cardiovasc Pharmacother 8:8 (2022), 756–767.
van der Meer, P., Rienstra, M., van Veldhuisen, D.J., A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?. Eur Heart J 43:23 (2022), 2221–2223.
Swedberg, K., Komajda, M., Böhm, M., et al. Ivabradine and Outcomes in Chronic Heart Failure (SHIFT): a randomised placebo-controlled study. Lancet 376:9744 (2010), 875–885.
Verrier, R.L., Bonatti, R., Silva, A.F.G., et al. If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation. Heart Rhythm 11:12 (2014), 2288–2296.
Fontenla, A., Tamargo, J., Salgado, R., et al. Ivabradine for controlling heart rate in permanent atrial fibrillation: a translational clinical trial. Heart Rhythm 20:6 (2023), 822–830.
Tanboğa, İ.H., Topçu, S., Aksakal, E., et al. The risk of atrial fibrillation with ivabradine treatment: a meta-analysis with trial sequential analysis of more than 40000 patients. Clin Cardiol 39:10 (2016), 615–620.
Chen, Y.C., Suenari, K., Cheng, C.C., et al. Effects of ivabradine on the pulmonary vein electrical activity and modulation of pacemaker currents and calcium homeostasis. J Cardiovasc Electrophysiol 23:2 (2012), 200–206.
Komajda, M., Isnard, R., Cohen-Solal, A., et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 19:11 (2017), 1495–1503.
Hardison, E., Cox, Z.L., Heckman, K., Kelly, P.A., Lindenfeld, J.A., A case report of ivabradine used for heart rate control of atrial fibrillation in acute decompensated heart failure. Eur Heart J Case Rep, 6(2), 2022, ytac077.
Taylor, A.L., Ziesche, S., Yancy, C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351:20 (2004), 2049–2057.
Taylor, A.L., Ziesche, S., Yancy, C.W., et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation 115:13 (2007), 1747–1753.
Armstrong, P.W., Pieske, B., Anstrom, K.J., et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:20 (2020), 1883–1893.
Teerlink, J.R., Diaz, R., Felker, G.M., et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 384:2 (2021), 105–116.
Kosiborod, M.N., Abildstrøm, S.Z., Borlaug, B.A., et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:12 (2023), 1069–1084.
Solomon, S.D., Claggett, B.L., Miao, Z.M., et al. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. Eur Heart J 43:23 (2022), 2212–2220.
Margulies, K.B., Hernandez, A.F., Redfield, M.M., et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316:5 (2016), 500–508.
Jorsal, A., Kistorp, C., Holmager, P., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19:1 (2017), 69–77.
Nauck, M.A., Meier, J.J., Cavender, M.A., El Aziz, M.A., Drucker, D.J., Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136:9 (2017), 849–870.
Fisher, M., Petrie, M.C., Ambery, P.D., Donaldson, J., McMurray, J.J.V., Ye, J., Cardiovascular safety of albiglutide in the Harmony Programme: a meta-analysis. Lancet Diabetes Endocrinol 3:9 (2015), 697–703.
Monami, M., Nreu, B., Scatena, A., et al. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. J Endocrinol Invest 40:11 (2017), 1251–1258.
Kirchhof, P., Camm, A.J., Goette, A., et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383:14 (2020), 1305–1316.
Packer, D.L., Piccini, J.P., Monahan, K.H., et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation 143:14 (2021), 1377–1390.
Marrouche, N.F., Brachmann, J., Andresen, D., et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378:5 (2018), 417–427.
Sohns, C., Fox, H., Marrouche, N.F., et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med 389:15 (2023), 1380–1389.
Zylla, M.M., Leiner, J., Rahm, A.K., et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Circ Heart Fail, 15(9), 2022, e009281.
Chieng, D., Sugumar, H., Segan, L., et al. Atrial fibrillation ablation for heart failure with preserved ejection fraction: a randomized controlled trial. J Am Coll Cardiol HF 11:6 (2023), 646–658.
Rillig, A., Magnussen, C., Ozga, A.K., et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation 144:11 (2021), 845–858.
Di Biase, L., Mohanty, P., Mohanty, S., et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 133 (2016), 1637–1644.
Gasparini, M., Leclercq, C., Lunati, M., et al. Cardiac resynchronization therapy in patients with atrial fibrillation. The CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). J Am Coll Cardiol HF 1:6 (2013), 500–507.
Brignole, M., Pentimalli, F., Palmisano, P., et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J 42:46 (2021), 4731–4739.
Brignole, M., Pokushalov, E., Pentimalli, F., et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 39:45 (2018), 3999–4008.
Butler, J., Packer, M., Filippatos, G., et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43:5 (2022), 416–426.
